Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM

被引:78
作者
Kimura, H
Suzuki, Y
Gejyo, F
Karasawa, R
Miyazaki, R
Suzuki, S
Arakawa, M
机构
[1] Fukui Med Sch, Dept Clin & Lab Sci, Fukui 91011, Japan
[2] Niigata Univ, Sch Med, Dept Med 2, Niigata, Japan
[3] Fujita Mem Hosp, Fukui, Japan
关键词
NIDDM; diabetic nephropathy; renal survival; apolipoprotein E polymorphism; hypertension;
D O I
10.1053/ajkd.1998.v31.pm9531184
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Hypercholesterolemia is a major determinant of the decline of renal function in patients with diabetes, Apolipoprotein E polymorphism may influence the metabolism of lipoprotein in diabetic patients. The purpose of this study was to investigate the association between genetic polymorphisms in apolipoprotein E and the progression of diabetic nephropathy in patients with non-insulin-dependent diabetes mellitus over a 10-year period (13 to 37 years; median, 20 years), Subjects with a stable renal function without overt proteinuria had a higher cholesterol level, lower incidences of hypertension and proliferative diabetic retinopathy, and a higher frequency of the E4 allele than subjects with a decline in renal function (end-stage renal failure requiring dialysis treatment), In the diabetic patients, the apolipoprotein E4 carriers had a higher cholesterol level than did the noncarriers. The survival rate from renal disease in the apolipoprotein E4 carriers was higher than in the noncarriers among the diabetic patients, Apolipoprotein E polymorphism and hypertension were identified as independent risk factors for the progression to renal failure, Results indicate that apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy, Presence of the apolipoprotein E4 allele is a protective factor, and other alleles are risk factors. (C) 1998 by the National Kidney Foundation, Inc.
引用
收藏
页码:666 / 673
页数:8
相关论文
共 41 条
[11]   APOLIPOPROTEIN-E ALLELE FREQUENCIES IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS WITH HYPERTRIGLYCERIDEMIA (TYPE-IIB, TYPE-III, TYPE-IV, AND TYPE-V HYPERLIPOPROTEINEMIA) [J].
ETO, M ;
WATANABE, K ;
MAKINO, I ;
ISHII, K .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (08) :776-780
[12]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[13]   DIABETIC CONTROL AND MICROVASCULAR COMPLICATIONS - THE NEAR-NORMOGLYCEMIC EXPERIENCE [J].
HANSSEN, KF ;
DAHLJORGENSEN, K ;
LAURITZEN, T ;
FELDTRASMUSSEN, B ;
BRINCHMANNHANSEN, O ;
DECKERT, T .
DIABETOLOGIA, 1986, 29 (10) :677-684
[14]  
HASSLACHER C, 1988, KIDNEY INT, V34, pS133
[15]  
HIXSON JE, 1990, J LIPID RES, V31, P545
[16]   APOLIPOPROTEIN E2, RENAL-FAILURE AND LIPID ABNORMALITIES IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
HORITA, K ;
ETO, M ;
MAKINO, I .
ATHEROSCLEROSIS, 1994, 107 (02) :203-211
[17]  
JEPPSSON JO, 1986, CLIN CHEM, V32, P1867
[18]  
KATAOKA S, 1994, CLIN CHEM, V40, P11
[19]  
KAYSEN GA, 1991, KIDNEY INT, V39, pS8
[20]  
KROLEWSKI AS, 1994, KIDNEY INT, V45, pS125